<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766441</url>
  </required_header>
  <id_info>
    <org_study_id>08/H1005/46</org_study_id>
    <nct_id>NCT00766441</nct_id>
  </id_info>
  <brief_title>Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan</brief_title>
  <official_title>Sitagliptin Versus Sulphonylurea Based Treatments in Muslim Patients With Type 2 Diabetes During Ramadan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess if Sitagliptin addition to metformin or glitazone is better than
      current sulphonylurea based treatments during Ramadan. The rationale is that Sitagliptin
      offers metabolic advantages primarily with the low incidence of hypoglycemia over current
      sulphonylurea based treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To define metabolic alterations during Ramadan:

        1. Primary end point: Occurrence of hypoglycemia. The patients will record hypoglycaemic
           episodes in a self-monitoring diary together with blood glucose values.

        2. Secondary endpoints: Body weight, fasting blood sugar (FBS), glycosylated haemoglobin
           (HbA1c)/Fructosamine, triglycerides (TG), total cholesterol (TC), low-density
           lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C).

        3. A subgroup will undergo CGMS assessment to define glycaemic excursions during and after
           fasting.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inadequate recruitment
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of hypoglycemia</measure>
    <time_frame>4 weeks during Ramadan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight, fasting blood sugar, HbA1c, triglycerides, total cholesterol, LDL-C, HDL-C. CGMS to define glycaemic excursions</measure>
    <time_frame>4 weeks during Ramadan</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulphonylurea</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>tablet, 100mg, once daily, 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulphonylurea</intervention_name>
    <description>sulphonylurea, variable, od or bd, during ramadan</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Muslim men and women with Type 2 diabetes.

          2. Age 18-78 years

          3. Intending to fast during the month of Ramadan

          4. On oral antihyperglycemic agents (sulphonylurea based/combination therapy)

        Exclusion Criteria:

          1. Patient with hypersensitivity or contraindication to Sitagliptin treatment

          2. Patient with CKD (creatinine clearance &lt;50 ml/min)

          3. Patients who have participated in another intervention study in the last 2 months

          4. Patients who do not give informed consent

          5. Pregnant or breast feeding women.

          6. Patients on insulin

          7. Patients with severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rayaz A Malik, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>January 11, 2010</last_update_submitted>
  <last_update_submitted_qc>January 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor R A Malik</name_title>
    <organization>University of Manchester</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>ramadan</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

